Medullary thyroid carcinoma – Adverse events during systemic treatment: risk-benefit ratio (2017)
Source: Archives of Endocrinology and Metabolism. Unidade: FMRP
Subjects: CARCINOMA NEUROENDÓCRINO, INIBIDORES DE ENZIMAS, PROTEÍNAS QUINASES, NEOPLASIAS DA TIREOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACIEL, Léa Maria Zanini e MAGALHÃES, Patricia KüMnzle Ribeiro. Medullary thyroid carcinoma – Adverse events during systemic treatment: risk-benefit ratio. Archives of Endocrinology and Metabolism, v. 61, n. 4, p. 398-402, 2017Tradução . . Disponível em: https://doi.org/10.1590/2359-3997000000267. Acesso em: 30 abr. 2024.APA
Maciel, L. M. Z., & Magalhães, P. K. M. R. (2017). Medullary thyroid carcinoma – Adverse events during systemic treatment: risk-benefit ratio. Archives of Endocrinology and Metabolism, 61( 4), 398-402. doi:10.1590/2359-3997000000267NLM
Maciel LMZ, Magalhães PKMR. Medullary thyroid carcinoma – Adverse events during systemic treatment: risk-benefit ratio [Internet]. Archives of Endocrinology and Metabolism. 2017 ; 61( 4): 398-402.[citado 2024 abr. 30 ] Available from: https://doi.org/10.1590/2359-3997000000267Vancouver
Maciel LMZ, Magalhães PKMR. Medullary thyroid carcinoma – Adverse events during systemic treatment: risk-benefit ratio [Internet]. Archives of Endocrinology and Metabolism. 2017 ; 61( 4): 398-402.[citado 2024 abr. 30 ] Available from: https://doi.org/10.1590/2359-3997000000267
